Feasibility and Outcome of Haploidentical Hematopoietic Stem Cell Transplantation with Post-Transplant High-Dose Cyclophosphamide for Children and Adolescents with Hematologic Malignancies: An AIEOP-GITMO Retrospective Multicenter Study

Appelbaum, 2009, Thomas' hematopoietic cell transplantation: stem cell transplantation, 10.1002/9781444303537 Kekre, 2014, Hematopoietic stem cell transplantation donor sources in the 21st century: choosing the ideal donor when a perfect match does not exist, Blood, 124, 334, 10.1182/blood-2014-02-514760 Falk, 1978, Bone marrow transplantation between a histocompatible parent and child for acute leukemia, Transplantation, 25, 88, 10.1097/00007890-197802000-00011 Dupont, 1979, Use of HLA genotypically different donors in bone marrow transplantation, Transplant Proc, 11, 219 O'Reilly, 1988, Allogeneic transplants depleted of T cells by soybean lectin applutination and E rosette depletion, Bone Marrow Transplant, 3, 3 Aversa, 1994, Successful engraftment of T-cell-depleted haploidentical “three loci” incompatible transplants in leukemia patients by addition of recombinant human granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells to bone marrow inoculum, Blood, 84, 3948, 10.1182/blood.V84.11.3948.bloodjournal84113948 Aversa, 1999, Improved outcome with T-cell depleted bone marrow transplantation for acute leukemia, J Clin Oncol, 17, 1545, 10.1200/JCO.1999.17.5.1545 Aversa, 1998, Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype, N Engl J Med, 339, 1186, 10.1056/NEJM199810223391702 Locatelli, 2013, Negative depletion of α/β T cells and CD19+ B lymphocytes: a novel frontier to optimize the effect of innate immunity in HLA-mismatched hematopoietic stem cell transplantation, Immunol Lett, 155, 21, 10.1016/j.imlet.2013.09.027 Bertaina, 2014, HLA-haploidentical stem cell transplantation after removal of α/β+ T and B cells in children with nonmalignant disorders, Blood, 124, 822, 10.1182/blood-2014-03-563817 Reisner, 2011, Haploidentical hematopoietic transplantation: current status and future perspectives, Blood, 118, 6006, 10.1182/blood-2011-07-338822 Bader, 2011, Rapid immune recovery and low TRM in haploidentical stem cell transplantation in children and adolescents using CD3/CD19-depleted stem cells, Best Pract Res Clin Haematol, 24, 331, 10.1016/j.beha.2011.04.005 Owens, 1971, The effect of cytotoxic drugs on graft-versus-host disease in mice, Transplantation, 11, 378, 10.1097/00007890-197104000-00004 Jones, 1995, Assessment of aldhehyde dehydrogenase in viable cells, Blood, 85, 2742, 10.1182/blood.V85.10.2742.bloodjournal85102742 Luznik, 2008, HLA-haploidentical bone marrow transplantation for hematological malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide, Biol Blood Marrow Transplant, 14, 641, 10.1016/j.bbmt.2008.03.005 Santos, 1987, Cyclosporine plus methylprednisolone versus cyclophosphamide plus methylprednisolone as prophylaxis for graft-versus-host disease: a randomized, double-blind study in patients undergoing allogeneic marrow transplantation, Clin Transplant, 1, 21 Mayumi, 1996, Cyclophosphamide-induced immunological tolerance: an overview, Immunobiology, 195, 129, 10.1016/S0171-2985(96)80033-7 Nomoto, 1992, Interference with cyclophosphamide-induced skin allograft tolerance by cyclosporine A, J Immunol, 149, 2668, 10.4049/jimmunol.149.8.2668 Luznik, 2012, Post-transplantation cyclophosphamide for tolerance induction in HLA-haploidentical BMT, Semin Oncol, 39, 6, 10.1053/j.seminoncol.2012.09.005 Ruggeri, 2002, Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants, Science, 295, 2097, 10.1126/science.1068440 Glucksberg, 1974, Clinical manifestations of graft-vs-host disease in human recipients of marrow from HLA-matched sibling donors, Transplantation, 18, 295, 10.1097/00007890-197410000-00001 Filipovich, 2005, National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease. I. Diagnosis and Staging Working Group report, Biol Blood Marrow Transplant, 11, 945, 10.1016/j.bbmt.2005.09.004 Kaplan, 1958, Nonparametric estimation from incomplete observation, J Am Stat Assoc, 53, 457, 10.1080/01621459.1958.10501452 Gooley, 1999, Estimation of failure probabilities in the presence of competing risk: new representation of old estimators, Stat Med, 18, 695, 10.1002/(SICI)1097-0258(19990330)18:6<695::AID-SIM60>3.0.CO;2-O Gray, 1988, A class of K-sample tests for comparing the cumulative incidence of a competing risk, Ann Stat, 16, 1141, 10.1214/aos/1176350951 Im, 2015, Haploidentical hematopoietic stem cell transplantation in children and adolescents with acquired severe aplastic anemia, Korean J Pediatr, 58, 199, 10.3345/kjp.2015.58.6.199 Balashov, 2015, Single-center experience of unrelated and haploidentical stem cell transplantation with TCRαβ and CD19 depletion in children with primary immunodeficiency syndromes, Biol Blood Marrow Transplant, 21, 1955, 10.1016/j.bbmt.2015.07.008 Kruchen, 2015, Donor choice in haploidentical stem cell transplantation: fetal microchimerism is associated with better outcome in pediatric leukemia patients, Bone Marrow Transplant, 50, 1367, 10.1038/bmt.2015.136 Arcese, 2015, Haploidentical, G-CSF-primed, unmanipulated bone marrow transplantation for patients with high-risk hematological malignancies: an update, Bone Marrow Transplant, 50, S24, 10.1038/bmt.2015.91 Berger, 2008, Lymphocyte subsets recovery following allogeneic bone marrow transplantation (BMT): CD4+ cell count and transplant-related mortality, Bone Marrow Transplant, 41, 55, 10.1038/sj.bmt.1705870 Montagna, 2006, Single cell cloning of human, donor-derived antileukemia, T-cell lines for in vitro separation of graft-vs-leukemia effect from graft-vs-host reaction, Cancer Res, 66, 7310, 10.1158/0008-5472.CAN-06-0591 Bashey, 2014, T-cell replete haploidentical donor transplantation using post-transplant CY: an emerging standard-of-care option for patients who lack an HLA-identical sibling donor, Bone Marrow Transplant, 49, 999, 10.1038/bmt.2014.62 Huang, 2013, donor selection for haploidentical hematopoietic stem cell transplantation: who is the better—donor-recipient risk factor analysis, Blood, 122, 705, 10.1182/blood.V122.21.705.705 Bacigalupo, 2015, Unmanipulated haploidentical bone marrow transplantation and post-transplant cyclophosphamide for hematologic malignancies following a myeloablative conditioning: an update, Bone Marrow Transplant, 50, S37, 10.1038/bmt.2015.93 Hsu, 2005, Improved outcome in HLA-identical sibling hematopoietic stem cell transplantation for acute myelogenous leukemia (AML) predicted by KIR and HLA genotypes, Blood, 105, 4878, 10.1182/blood-2004-12-4825 Zhao, 2007, Prognosis after unmanipulated HLA-haploidentical blood and marrow transplantation is correlated to the numbers of KIR ligands in recipients, Eur J Haematol, 78, 338, 10.1111/j.1600-0609.2007.00822.x Ruggeri, 2007, Donor natural killer cell allorecognition of missing self in haploidentical hematopoietic transplantation for acute myeloid leukemia: challenging its predictive value, Blood, 110, 433, 10.1182/blood-2006-07-038687 Gagne, 2002, Relevance of KIR gene polymorphisms in bone marrow transplantation outcome, Hum Immunol, 63, 271, 10.1016/S0198-8859(02)00373-7